KKR, a global investment firm, agreed to acquire a stake in Immedica, a pharmaceutical company, from Impilo, a Nordic healthcare investment firm. Financial terms were not disclosed. “The Immedica team is one of the best that we have encountered in a space that we have been following for some time. We are deeply impressed by the accomplishments of Immedica under Impilo’s ownership and the establishment of a rare disease player with a highly promising pipeline. We look forward to working with the management team alongside Impilo to accelerate growth further,” Kugan Sathiyanandarajah, KKR Partner and Head of Health Care Strategic Growth Europe.